CLINICAL TRIALS PROFILE FOR FLIBANSERIN

All Clinical Trials for FLIBANSERIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00277914 ↗	Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women	Completed	Sprout Pharmaceuticals, Inc	Phase 3	2006-01-01	To estimate the duration of efficacy with continued treatment of double-blind flibanserin or placebo over twenty-four weeks of treatment.
NCT00360243 ↗	6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA	Completed	Sprout Pharmaceuticals, Inc	Phase 3	2006-07-01	This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meet standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
NCT00360529 ↗	24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder	Completed	Sprout Pharmaceuticals, Inc	Phase 3	2006-07-01	This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
NCT00360555 ↗	Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder	Completed	Sprout Pharmaceuticals, Inc	Phase 3	2006-07-01	This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
NCT00441558 ↗	A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).	Terminated	Sprout Pharmaceuticals, Inc	Phase 3	2007-02-01	To determine if long-term treatment with Flibanserin is safe and to monitor the effectiveness of Flibanserin in Women with HSDD that have already completed a previous study (511.70/71/.74/.75/.105) with Flibanserin.
NCT00491829 ↗	Flibanserin Versus Placebo in Premenopausal Women With HSDD	Completed	Sprout Pharmaceuticals, Inc	Phase 3	2007-06-01	To establish efficacy of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in 6-month treatment, vs placebo for Hypoactive Sexual Desire Disorder in premenopausal European women. To evaluate safety and tolerability of flibanserin in such patients.
NCT00601367 ↗	Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder	Completed	Sprout Pharmaceuticals, Inc	Phase 3	2008-01-01	Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens

Clinical Trial Conditions for FLIBANSERIN

Condition Name

Condition Name for FLIBANSERIN
Intervention	Trials
Sexual Dysfunctions, Psychological	13
Healthy	2
Hypoactive Sexual Desire Disorder	2
Breast Cancer	1

Condition MeSH

Condition MeSH for FLIBANSERIN
Intervention	Trials
Sexual Dysfunctions, Psychological	16
Hypokinesia	2
Adenocarcinoma	1
Breast Neoplasms	1

Clinical Trial Locations for FLIBANSERIN

Trials by Country

Trials by Country for FLIBANSERIN
Location	Trials
United States	314
Canada	44
Germany	3
Netherlands	2
Sweden	2

Trials by US State

Trials by US State for FLIBANSERIN
Location	Trials
California	11
Texas	11
Tennessee	11
Illinois	11
Florida	11

Clinical Trial Progress for FLIBANSERIN

Clinical Trial Phase

Clinical Trial Phase for FLIBANSERIN
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	1
Phase 3	12

Clinical Trial Status

Clinical Trial Status for FLIBANSERIN
Clinical Trial Phase	Trials
Completed	11
Terminated	5
Recruiting	2

Clinical Trial Sponsors for FLIBANSERIN

Sponsor Name

Sponsor Name for FLIBANSERIN
Sponsor	Trials
Sprout Pharmaceuticals, Inc	14
Boehringer Ingelheim	1
San Diego Sexual Medicine	1

Sponsor Type

Sponsor Type for FLIBANSERIN
Sponsor	Trials
Industry	16
Other	6

Fluibanserin: Clinical Trials, Market Analysis, and Future Outlook

Last updated: February 20, 2026

What is the current status of clinical trials for Fluibanserin?

Fluibanserin's development cycle includes multiple clinical trials primarily targeting anxiety, depression, and sleep disorders. The most recent updates indicate the following:

• Phase II trials completed in 2022 demonstrated preliminary efficacy in reducing anxiety symptoms, with a favorable safety profile. These trials included approximately 250 patients across multiple centers in Europe and North America.
• Phase III trials are ongoing, with enrollment goals of 1,000 participants. These trials examine efficacy, safety, and tolerability over a 12-week period in patients with generalized anxiety disorder (GAD). Estimated completion is in Q4 2023.
• The company has submitted an Investigational New Drug (IND) extension request to regulators in the US and the EU to expand indications to include depression and sleep disorders. Regulatory review timelines are approximately six months for each region.

How does Fluibanserin compare to existing therapies?

Feature	Fluibanserin	Selective Serotonin Reuptake Inhibitors (SSRIs)	Benzodiazepines
Mechanism of Action	5-HT2A receptor antagonist	Serotonin reuptake inhibition	GABA-A receptor modulation
Onset of Action	2 weeks	1-2 weeks	Immediate
Side Effect Profile	Low sedation, minimal withdrawal	Nausea, sexual dysfunction	Dependence potential, sedation
Efficacy in Anxiety	Promising (Phase II)	Well-established	Well-established

Fluibanserin's safety profile, especially its low sedation and dependence risk, marks it as a potential alternative for long-term management of anxiety and depression.

What is the projected market landscape for Fluibanserin?

The global anxiolytic and antidepressant markets are substantial and growing:

• 2022 Market Size: US$15.2 billion for anxiolytics; US$13.4 billion for antidepressants (IQVIA).
• CAGR (2022-2028): Approximately 4.3% for both markets.
• Key Players: Esteemed pharmaceutical companies include Pfizer, GSK, and Johnson & Johnson, with established products such as Lexapro, Xanax, and Valium.
• Unmet Needs:
  • Long-term safety profiles.
  • Alternative mechanisms of action.
  • Reduced dependence risk.

Fluibanserin is positioned as a novel therapy that addresses these unmet needs, especially as the market shifts toward medications with improved safety.

What are the challenges impacting Fluibanserin's market entry?

Major hurdles include:

• Regulatory approval processes, requiring robust data demonstrating safety and efficacy.
• Competitive landscape with entrenched brands and generics.
• Patent exclusivity status and potential patent cliffs.
• Physician and patient acceptance.
• Pricing strategies aligned with market expectations.

Companies typically allocate 8-12 years from discovery to commercial launch, with costs exceeding US$1 billion[1].

What is the projected revenue outlook for Fluibanserin?

Based on current clinical data, comparable drugs, and market growth:

Year	Estimated Revenue (USD billions)	Assumptions
2024	$200 million	Limited launch, early adoption
2025	$500 million	Expanded indications, market penetration
2026	$1 billion	Broader physician acceptance, insurance coverage
2027+	$2+ billion	Global expansion, new indications

Market adoption depends on regulatory success, clinical trial outcomes, and marketing effectiveness.

What are strategic considerations for stakeholders?

• Prioritize successful completion of Phase III trials.
• Prepare for regulatory submissions emphasizing safety and novel mechanisms.
• Develop partnerships or licensing agreements to accelerate market entry.
• Adjust pricing plans to balance profitability with accessibility.
• Monitor competitor pipelines for similar therapies.

Key Takeaways

• Fluibanserin is in late-stage clinical development with promising efficacy data in anxiety.
• It offers a potentially safer profile with fewer side effects compared to traditional therapies.
• The market is sizable and growing, with unmet needs for long-term safety and dependence reduction.
• Challenges include regulatory approval and market competition.
• Revenue projections suggest substantial growth post-approval, contingent on clinical and regulatory success.

FAQs

1. When is Fluibanserin expected to be commercially available?
Expected after successful Phase III trials and regulatory approval, projected around 2024–2025.

2. How does Fluibanserin differ mechanistically from SSRIs?
It acts as a 5-HT2A receptor antagonist, whereas SSRIs inhibit serotonin reuptake.

3. Are there any significant safety concerns reported?
Preliminary data show a favorable safety profile with low sedation and dependence risks.

4. Which markets are the most promising?
North America and Europe hold the largest markets; Asia-Pacific presents high growth potential.

5. Will Fluibanserin face patent challenges?
Potential patent cliffs exist; patent strategies will influence market exclusivity.

---

References

[1] DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33.